desvenlafaxine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4380	93413-62-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: desvenlafaxine desvenlafaxine succinate pristiq DVS-233 desvenlafaxine fumarate	The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). Molecular weight: 263.38 Formula: C16H25NO2 CLOGP: 2.68 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 43.70 ALOGS: -2.27 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

desvenlafaxine
desvenlafaxine succinate
pristiq
DVS-233
desvenlafaxine fumarate

The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).

Molecular weight: 263.38
Formula: C16H25NO2
CLOGP: 2.68
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 43.70
ALOGS: -2.27
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	572 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	45 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.42 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	3.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.70 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 29, 2008	FDA	WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product residue present	726.26	16.05	195	20904	3687	46661276
Drug withdrawal syndrome	585.58	16.05	273	20826	27111	46637852
Suicidal ideation	327.08	16.05	241	20858	56141	46608822
Anxiety	270.67	16.05	370	20729	181587	46483376
Feeling abnormal	267.14	16.05	305	20794	124755	46540208
Crying	264.82	16.05	147	20952	20994	46643969
Withdrawal syndrome	254.62	16.05	136	20963	17998	46646965
Insomnia	216.38	16.05	316	20783	164608	46500355
Depression	206.08	16.05	314	20785	169790	46495173
Irritability	168.26	16.05	124	20975	28822	46636141
Dizziness	151.30	16.05	414	20685	340000	46324963
Anger	141.79	16.05	80	21019	11772	46653191
Nausea	113.72	16.05	609	20490	686845	45978118
Hyperhidrosis	109.48	16.05	166	20933	89142	46575821
Condition aggravated	106.57	16.05	296	20803	244756	46420207
Headache	105.73	16.05	461	20638	477891	46187072
Panic attack	89.95	16.05	74	21025	20168	46644795
Nervousness	84.70	16.05	83	21016	28392	46636571
Emotional disorder	83.54	16.05	58	21041	12266	46652697
Intentional product misuse	80.79	16.05	103	20996	47025	46617938
Agitation	79.49	16.05	111	20988	55304	46609659
Abnormal dreams	78.30	16.05	52	21047	10227	46654736
Tremor	77.26	16.05	165	20934	115474	46549489
Feeling jittery	75.06	16.05	52	21047	10956	46654007
Drug ineffective	61.52	16.05	518	20581	677320	45987643
Thinking abnormal	59.15	16.05	43	21056	9771	46655192
Nightmare	56.23	16.05	52	21047	16546	46648417
Death	49.85	16.05	47	21052	335501	46329462
Suicide attempt	49.43	16.05	89	21010	54947	46610016
Serotonin syndrome	48.05	16.05	57	21042	24163	46640800
Completed suicide	47.08	16.05	159	20940	145761	46519202
Acute kidney injury	46.97	16.05	24	21075	235831	46429132
Middle insomnia	46.96	16.05	37	21062	9478	46655485
Anaemia	45.30	16.05	30	21069	255749	46409214
Depressed mood	45.18	16.05	65	21034	33254	46631709
Neutropenia	44.53	16.05	6	21093	143198	46521765
Disturbance in attention	43.42	16.05	62	21037	31498	46633465
Overdose	42.99	16.05	122	20977	101857	46563106
Rheumatoid arthritis	42.77	16.05	28	21071	240187	46424776
Pyrexia	41.88	16.05	58	21041	348744	46316219
Paraesthesia	41.49	16.05	132	20967	117305	46547658
Weight increased	41.10	16.05	165	20934	164308	46500655
Migraine	40.07	16.05	94	21005	69932	46595031
Mydriasis	39.55	16.05	35	21064	10518	46654445
Mania	38.73	16.05	35	21064	10811	46654152
Vision blurred	38.22	16.05	100	20999	79608	46585355
Energy increased	38.11	16.05	19	21080	2175	46662788
Anorgasmia	37.63	16.05	13	21086	585	46664378
Tinnitus	36.08	16.05	53	21046	27620	46637343
Drug screen positive	35.35	16.05	22	21077	3869	46661094
Coma scale abnormal	34.95	16.05	24	21075	4982	46659981
Impaired driving ability	33.70	16.05	22	21077	4202	46660761
Thrombocytopenia	33.53	16.05	8	21091	126573	46538390
Seizure	32.78	16.05	126	20973	122928	46542035
Drug screen false positive	32.78	16.05	13	21086	864	46664099
Product substitution issue	32.53	16.05	37	21062	14994	46649969
Pneumonia	32.26	16.05	77	21022	376243	46288720
Mood altered	31.57	16.05	34	21065	12973	46651990
Blood pressure increased	30.77	16.05	126	20973	126540	46538423
Aggression	30.29	16.05	44	21055	22700	46642263
Prescribed overdose	30.21	16.05	30	21069	10419	46654544
Sepsis	29.92	16.05	12	21087	136002	46528961
Mood swings	28.59	16.05	36	21063	16216	46648747
Drug hypersensitivity	28.41	16.05	198	20901	243627	46421336
Hostility	27.27	16.05	13	21086	1349	46663614
Bruxism	27.26	16.05	17	21082	3000	46661963
Restlessness	26.47	16.05	44	21055	25480	46639483
Somnolence	26.43	16.05	140	20959	156381	46508582
Nonspecific reaction	26.29	16.05	14	21085	1836	46663127
Amnesia	25.03	16.05	57	21042	41574	46623389
Paranoia	24.50	16.05	27	21072	10570	46654393
Libido decreased	24.35	16.05	15	21084	2590	46662373
Maternal exposure during pregnancy	24.33	16.05	8	21091	102541	46562422
Panic reaction	24.15	16.05	17	21082	3672	46661291
Therapeutic response unexpected	23.45	16.05	32	21067	15584	46649379
Palpitations	23.31	16.05	95	21004	95164	46569799
Pre-existing condition improved	22.94	16.05	21	21078	6591	46658372
Abnormal behaviour	22.78	16.05	37	21062	21021	46643942
Dyspnoea	22.41	16.05	139	20960	515409	46149554
Mental disorder	22.38	16.05	38	21061	22387	46642576
Hypersensitivity vasculitis	22.10	16.05	17	21082	4204	46660759
Euphoric mood	21.92	16.05	17	21082	4255	46660708
Tachyphrenia	21.87	16.05	11	21088	1283	46663680
Loss of libido	21.43	16.05	11	21088	1338	46663625
Febrile neutropenia	21.38	16.05	8	21091	94619	46570344
General physical health deterioration	21.26	16.05	13	21086	115756	46549207
Apathy	21.25	16.05	21	21078	7247	46657716
Post-traumatic stress disorder	20.53	16.05	16	21083	4032	46660931
Muscle twitching	20.43	16.05	29	21070	14643	46650320
Haemoglobin decreased	20.37	16.05	17	21082	128932	46536031
Unevaluable event	20.18	16.05	56	21043	46119	46618844
Bradycardia	20.08	16.05	3	21096	66295	46598668
Drug effective for unapproved indication	20.05	16.05	11	21088	1531	46663432
Negative thoughts	20.03	16.05	9	21090	816	46664147
Urinary tract infection	18.89	16.05	45	21054	220221	46444742
Stomatitis	18.71	16.05	4	21095	68293	46596670
Intestinal pseudo-obstruction	18.53	16.05	8	21091	659	46664304
Peripheral swelling	18.21	16.05	27	21072	158044	46506919
Dissociation	18.04	16.05	11	21088	1866	46663097
Blood cholesterol increased	17.95	16.05	49	21050	39964	46624999
Treatment failure	17.73	16.05	10	21089	93077	46571886
Suicidal behaviour	17.72	16.05	12	21087	2436	46662527
Change in seizure presentation	17.45	16.05	6	21093	266	46664697
Renal impairment	17.29	16.05	6	21093	74366	46590597
Food craving	16.92	16.05	9	21090	1178	46663785
Respiratory failure	16.92	16.05	11	21088	94805	46570158
Coma	16.86	16.05	3	21096	58346	46606617
Joint swelling	16.69	16.05	31	21068	166042	46498921
Septic shock	16.68	16.05	3	21096	57890	46607073
Hallucination	16.58	16.05	55	21044	49896	46615067
Brain injury	16.57	16.05	17	21082	6133	46658830
Stress	16.44	16.05	56	21043	51495	46613468
Wrong technique in product usage process	16.38	16.05	58	21041	54364	46610599
Impaired work ability	16.18	16.05	24	21075	12612	46652351
Impatience	16.13	16.05	6	21093	335	46664628
Affect lability	16.11	16.05	19	21080	8001	46656962

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product residue present	227.03	23.59	60	5630	2618	29944170
Drug withdrawal syndrome	162.71	23.59	78	5612	19731	29927057
Serotonin syndrome	136.50	23.59	67	5623	17824	29928964
Suicidal ideation	111.65	23.59	75	5615	36039	29910749
Anxiety	96.24	23.59	101	5589	89770	29857018
Depression	76.70	23.59	90	5600	90347	29856441
Overdose	63.42	23.59	79	5611	84258	29862530
Suicide attempt	61.67	23.59	53	5637	36644	29910144
Sexual dysfunction	56.50	23.59	26	5664	5975	29940813
Hyperhidrosis	52.26	23.59	64	5626	67026	29879762
Insomnia	51.19	23.59	75	5615	93261	29853527
Drug ineffective	50.43	23.59	160	5530	340227	29606561
Anger	49.14	23.59	29	5661	11091	29935697
Withdrawal syndrome	48.83	23.59	29	5661	11221	29935567
Feeling abnormal	42.34	23.59	53	5637	56703	29890085
Thinking abnormal	40.78	23.59	20	5670	5291	29941497
Completed suicide	38.18	23.59	68	5622	99424	29847364
Mania	33.09	23.59	21	5669	9133	29937655
Coma scale abnormal	32.94	23.59	15	5675	3361	29943427
Dry mouth	32.39	23.59	30	5660	22820	29923968
Nervousness	30.54	23.59	22	5668	11766	29935022
Libido decreased	28.64	23.59	15	5675	4551	29942237
Drug screen positive	26.29	23.59	14	5676	4393	29942395
Headache	26.18	23.59	85	5605	182221	29764567
Erectile dysfunction	26.11	23.59	24	5666	18078	29928710
Abnormal behaviour	25.90	23.59	28	5662	25595	29921193
Bipolar disorder	25.39	23.59	13	5677	3763	29943025
Paralysis	25.05	23.59	15	5675	5886	29940902
Irritability	24.74	23.59	26	5664	23024	29923764
Paraesthesia	24.59	23.59	40	5650	54287	29892501
Drug screen false positive	24.49	23.59	8	5682	731	29946057
Tremor	24.49	23.59	48	5642	75315	29871473
Emotional disorder	24.39	23.59	14	5676	5080	29941708
Condition aggravated	24.19	23.59	69	5621	137797	29808991
Acute kidney injury	24.08	23.59	11	5679	273831	29672957
Vasoplegia syndrome	23.81	23.59	9	5681	1262	29945526
Intentional product misuse	23.66	23.59	31	5659	34636	29912152

Pharmacologic Action:

Source	Code	Description
ATC	N06AX23	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
FDA MoA	N0000000102	Norepinephrine Uptake Inhibitors
FDA MoA	N0000000109	Serotonin Uptake Inhibitors
FDA EPC	N0000175749	Serotonin and Norepinephrine Reuptake Inhibitor
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D000068760	Serotonin and Noradrenaline Reuptake Inhibitors
FDA MoA	N0000182137	Cytochrome P450 2D6 Inhibitors
CHEBI has role	CHEBI:35469	thymoanaleptics
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:83399	marine xenobiotic metabolites

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000
Generalized anxiety disorder	off-label use	21897009	DOID:14320
Social phobia	off-label use	25501002	DOID:11257
Menopausal flushing	off-label use	198436008
Neuropathic pain	off-label use	247398009
Panic disorder	off-label use	371631005	DOID:594
Ocular hypertension	contraindication	4210003	DOID:9282
Suicidal thoughts	contraindication	6471006
Hypercholesterolemia	contraindication	13644009
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Cerebrovascular disease	contraindication	62914000	DOID:6713
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hyponatremia	contraindication	89627008
Seizure disorder	contraindication	128613002
Bleeding	contraindication	131148009
Impaired renal function disorder	contraindication	197663003
Mania	contraindication	231494001
Hypomania	contraindication	231496004
Interstitial lung disease	contraindication	233703007	DOID:3082
Disease of liver	contraindication	235856003	DOID:409
Hypertriglyceridemia	contraindication	302870006
Serotonin syndrome	contraindication	371089000
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.79	acidic
pKa2	9.33	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	Feb. 6, 2021	ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1
EQ 25MG BASE	PRISTIQ	PF PRISM CV	N021992	Aug. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	Feb. 6, 2021	ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1
EQ 50MG BASE	PRISTIQ	PF PRISM CV	N021992	Feb. 29, 2008	RX	TABLET, EXTENDED RELEASE	ORAL	Feb. 6, 2021	ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	6.27	WOMBAT-PK	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	7.33	WOMBAT-PK	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.22	CHEMBL

External reference:

ID	Source
D07793	KEGG_DRUG
4027338	VUID
N0000176142	NUI
93414-04-1	SECONDARY_CAS_RN
4027338	VANDF
C1880288	UMLSCUI
CHEBI:83527	CHEBI
CHEMBL1118	ChEMBL_ID
CHEMBL3989861	ChEMBL_ID
CHEMBL1201728	ChEMBL_ID
DB06700	DRUGBANK_ID
D000069468	MESH_DESCRIPTOR_UI
125017	PUBCHEM_CID
7158	IUPHAR_LIGAND_ID
8361	INN_ID
NG99554ANW	UNII
683693	RXNORM
132507	MMSL
200628	MMSL
25184	MMSL
339716	MMSL
38906	MMSL
d07113	MMSL
012574	NDDF
012575	NDDF
015249	NDDF
430267008	SNOMEDCT_US
430271006	SNOMEDCT_US
433292007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1210	TABLET, EXTENDED RELEASE	25 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1211	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	31 sections
Pristiq Extended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	0008-1222	TABLET, EXTENDED RELEASE	100 mg	ORAL	NDA	31 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0400	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0401	TABLET, FILM COATED, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0603	TABLET, FILM COATED, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3659	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3660	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4060	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	35208-009	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	35208-010	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
PristiqExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	43063-262	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	31 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-152	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-153	TABLET, EXTENDED RELEASE	100 mg	ORAL	NDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-540	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-541	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	46708-542	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4069	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA AUTHORIZED GENERIC	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4388	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4806	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	50090-5274	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	50090-5293	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-021	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-022	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-023	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	51991-006	TABLET, EXTENDED RELEASE	25 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	51991-311	TABLET, EXTENDED RELEASE	50 mg	ORAL	ANDA	30 sections
Desvenlafaxine	Human Prescription Drug Label	1	51991-312	TABLET, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
PristiqExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	54868-2932	TABLET, EXTENDED RELEASE	50 mg	ORAL	NDA	33 sections
Desvenlafaxine Succinate	HUMAN PRESCRIPTION DRUG LABEL	1	59762-1210	TABLET, EXTENDED RELEASE	25 mg	ORAL	NDA AUTHORIZED GENERIC	31 sections